Ligand id: 3951

Name: ambrisentan

IUPHAR Pharmacology Education Project (PEP) logo

View more information in the IUPHAR Pharmacology Education Project: ambrisentan

Structure and Physico-chemical Properties

2D Structure
Calculated Physico-chemical Properties
Hydrogen bond acceptors 5
Hydrogen bond donors 1
Rotatable bonds 7
Topological polar surface area 81.54
Molecular weight 378.16
XLogP 6.66
No. Lipinski's rules broken 1

Molecular properties generated using the CDK

No information available.
Summary of Clinical Use
Approved to treat pulmonary arterial hypertension (PAH).
Ambrisentan is being evaluated in Phase III clinical trial for the additional indication chronic thromboembolic pulmonary hypertension.
Mechanism Of Action and Pharmacodynamic Effects
Ambrisentan is a selective endothelin receptor A (ETA) antagonist. Antagonism of endothelin binding to ETA decreases vasoconstriction in the smooth muscle of the lungs and reduces pulmonary blood pressure.